Compare UNH & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | AZN |
|---|---|---|
| Founded | 1977 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.1B | 316.4B |
| IPO Year | 2010 | N/A |
| Metric | UNH | AZN |
|---|---|---|
| Price | $368.09 | $184.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 1 |
| Target Price | ★ $384.50 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 1.9M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.38% | 1.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.90 | N/A |
| Revenue | ★ $447,567,000,000.00 | N/A |
| Revenue This Year | N/A | $10.34 |
| Revenue Next Year | $3.64 | $6.43 |
| P/E Ratio | ★ $27.46 | $31.91 |
| Revenue Growth | ★ 11.81 | N/A |
| 52 Week Low | $234.60 | $66.16 |
| 52 Week High | $390.92 | $212.71 |
| Indicator | UNH | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 77.42 | 39.31 |
| Support Level | $350.83 | $182.39 |
| Resistance Level | $378.61 | $208.61 |
| Average True Range (ATR) | 8.37 | 2.96 |
| MACD | 0.90 | -1.70 |
| Stochastic Oscillator | 91.66 | 17.11 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.